Previsioni
Il prezzo obiettivo medio degli analisti è 10,02 € (+186,29%). La mediana è 9,11 € (+160,29%).
| Acquista |
11 |
| Mantieni |
3 |
| Vendi |
7 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
MannKind achieves positive phase‑1b results for inhaled nintedanib in IPF
MannKind reports positive topline results from the randomized, double‑blind phase‑1b study INFLO‑1 of inhaled nintedanib as a dry powder in patients with idiopathic pulmonary fibrosis (IPF). The 27‑patient study showed no serious adverse events, no drug‑related gastrointestinal side effects, no bronchospasms and no discontinuations or dose reductions; cough was mostly mild and transient. Overall, IPF patients received about 450 inhalations; combined with phase‑1a, 48 people were treated, 18 of them with IPF. The global phase‑2 study INFLO‑2 to further evaluate nintedanib DPI is currently recruiting and is expected to enroll around 210 participants. » Altro su de.investing.com
Wells Fargo upgrades MannKind after pediatric Afrezza approval, calls commercial potential a “show‑me story”
Wells Fargo raised its price target on MannKind to $11 and kept an Overweight rating, citing FDA approval of Afrezza for patients aged 6 and older and supportive INHALE‑1 data. The approval expands Afrezza’s market to pediatric patients and caregivers. MannKind also highlighted potential near‑term upside from up to $35 million in development milestones, a 10% royalty on net sales and its role as sole manufacturer of Tyvaso DPI. » Altro su finance.yahoo.com
MannKind completes patient recruitment for INFLO‑1 and starts global phase‑2 for Nintedanib DPI
MannKind has completed randomization of patients in the phase‑1b trial INFLO‑1 and has enrolled the first patient in the global phase‑2 trial INFLO‑2 for Nintedanib DPI. INFLO‑1 evaluates safety, tolerability and pharmacokinetics; results are expected in Q3 2026. INFLO‑2 aims to recruit about 210 participants at roughly 85 sites in a randomized, double‑blind 1:1:1 design over 12 weeks (with a 24‑week open extension) for dose finding and safety assessment. » Altro su de.investing.com
MannKind: shareholders re-elect nine directors, approve compensation and auditor
At the annual general meeting, shareholders re-elected all nine nominated MannKind directors and voted in an advisory capacity to approve the board’s compensation. Deloitte & Touche was confirmed as the independent auditor for the fiscal year ending December 31, 2026. In quarterly results, MannKind reported a 15% revenue rise to $90 million, mainly driven by FUROSCIX following the acquisition of scPharmaceuticals, but missed the EPS forecast of -$0.01 with a non-GAAP net loss of $0.02 per share. » Altro su de.investing.com
MannKind records Q1 revenue up 15% and sees three near-term regulatory catalysts
MannKind reported Q1 2026 revenue of $90 million (up 15% year-over-year), driven by the integration of FUROSCIX; the adjusted non-GAAP result showed a loss of $6.9 million. Management emphasizes strategic diversification away from a one-product model and identifies three imminent value drivers: Afrezza Pediatrics (PDUFA May 29), the FUROSCIX ReadyFlow autoinjector (PDUFA July 26), and nintedanib DPI with topline data in Q3 and the start of Phase 2 recruitment. The partnership with United Therapeutics for Ralinepag DPI was also expanded, including an upfront payment and milestones, and the revenue outlook for FUROSCIX in 2026 remains $110–120 million. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2022, MannKind Co. ha già distribuito 7,52 € di dividendi. L'ultimo pagamento è avvenuto a settembre 2022.
Dati finanziari
Nell'ultimo trimestre, MannKind Co. ha registrato ricavi pari a 89,94 Mln € e un utile netto di -20,5 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 89,94 Mln | 28,51% |
| Utile lordo | 69,18 Mln | 31,09% |
| Utile netto | -20,5 Mln | 401,33% |
| EBITDA | -4,73 Mln | 131,10% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,15 Mld € |
Numero di azioni | 321,64 Mln |
Massimo/minimo a 52 settimane | 5,93 € - 2,03 € |
| Dividendi | No |
Beta | 1,09 |
Rapporto P/E | -16,62 |
Rapporto PEG | 0,16 |
Rapporto P/B | -33,64 |
Rapporto P/S | 3,05 |
Profilo aziendale
MannKind Corporation, una società biofarmaceutica, si concentra sullo sviluppo e sulla commercializzazione di prodotti terapeutici per inalazione per le malattie endocrine e le malattie polmonari orfane negli Stati Uniti. Offre Afrezza, un'insulina per inalazione utilizzata per migliorare il controllo glicemico negli adulti con diabete. Promuove inoltre Thyquidity presso endocrinologi per adulti e pediatrici e altri operatori sanitari per il trattamento dell'ipotiroidismo. La società ha un accordo di licenza e collaborazione con United Therapeutics Corporation. Ha inoltre un accordo con NRx Pharmaceuticals per sviluppare una formulazione in polvere secca di ZYESAMI (aviptadil), una forma sintetica del peptide intestinale vasoattivo umano, che aiuta a proteggere le cellule da condizioni infiammatorie. MannKind Corporation è stata costituita nel 1991 ed ha sede a Westlake Village, California.
| Nome | MannKind Co. |
| CEO | Michael E. Castagna |
| Sede centrale | Danbury,
ca Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 28/07/2004 |
| Dipendenti | 592 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | MNKD |
Frankfurt | NNFN.F |
Düsseldorf | NNFN.DU |
SIX | NNFN.SW |
München | NNFN.MU |